Jfs Wealth Advisors, LLC Prothena Corp Public LTD CO Transaction History

Jfs Wealth Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	SELL	$24.75 - $40.66 $49 - $81	-2 Reduced 50.0%	2 $0
Q2 2023 Aug 07, 2023	SELL	$48.26 - $78.59 $96 - $157	-2 Reduced 33.33%	4 $0
Q1 2023 Apr 19, 2023	SELL	$46.97 - $58.27 $46 - $58	-1 Reduced 14.29%	6 $0
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $156 - $195	3 Added 75.0%	7 $0
Q3 2022 Oct 21, 2022	BUY	$25.16 - $60.63 $25 - $60	1 Added 33.33%	4 $0
Q1 2022 May 02, 2022	BUY	$30.27 - $49.22 $90 - $147	3 New	3 $0

185

43.7M

251K

79.2K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $302M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.